The most practical clinical model included urinary HOXC6 and DLX1 mRNA levels, patient age, DRE results, and PSA density to differentiate higher-grade PCa in patients with a PSA less than 10 ng/mL. This evidence concerns the gene KLK3 and posterior cortical atrophy.